Unknown

Dataset Information

0

T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma.


ABSTRACT: The cancer-testis antigen NY-ESO-1 is expressed by many solid tumors and has limited expression by mature somatic tissues, making it a highly attractive target for tumor immunotherapy. Targeting NY-ESO-1 using engineered T cells has demonstrated clinical efficacy in the treatment of some adult tumors. Neuroblastoma is a significant cause of cancer mortality in children, and is a tumor type shown to be responsive to immunotherapies. We evaluated a large panel of primarily resected neuroblastoma samples and demonstrated that 23% express NY-ESO-1. After confirming antigen-specific activity of T cells genetically engineered to express an NY-ESO-1 directed high-affinity transgenic T cell receptor in vitro, we performed xenograft mouse studies assessing the efficacy of NY-ESO-1-targeted T cells in both localized and disseminated models of neuroblastoma. Disease responses were monitored by tumor volume measurement and in vivo bioluminescence. After delivery of NY-ESO-1 transgenic TCR T cells, we observed significant delay of tumor progression in mice bearing localized and disseminated neuroblastoma, as well as enhanced animal survival. These data demonstrate that NY-ESO-1 is an antigen target in neuroblastoma and that targeted T cells represent a potential therapeutic option for patients with neuroblastoma.

SUBMITTER: Singh N 

PROVIDER: S-EPMC4760344 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma.

Singh Nathan N   Kulikovskaya Irina I   Barrett David M DM   Binder-Scholl Gwendolyn G   Jakobsen Bent B   Martinez Daniel D   Pawel Bruce B   June Carl H CH   Kalos Michael D MD   Grupp Stephan A SA  

Oncoimmunology 20150812 1


The cancer-testis antigen NY-ESO-1 is expressed by many solid tumors and has limited expression by mature somatic tissues, making it a highly attractive target for tumor immunotherapy. Targeting NY-ESO-1 using engineered T cells has demonstrated clinical efficacy in the treatment of some adult tumors. Neuroblastoma is a significant cause of cancer mortality in children, and is a tumor type shown to be responsive to immunotherapies. We evaluated a large panel of primarily resected neuroblastoma s  ...[more]

Similar Datasets

| S-EPMC4767237 | biostudies-literature
2023-07-31 | GSE238192 | GEO
| S-EPMC3277288 | biostudies-literature
| S-EPMC7394304 | biostudies-literature
| S-EPMC6192300 | biostudies-literature
| S-EPMC10508181 | biostudies-literature
| S-EPMC1570182 | biostudies-literature
| S-EPMC7088937 | biostudies-literature
| S-EPMC5941317 | biostudies-literature
| S-EPMC2561074 | biostudies-literature